CBUS Key Statistics, Chart & Performance
The current stock price of CBUS is 2.21 USD. In the past month the price increased by 25.47%. In the past year, price decreased by -15.83%.
CBUS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.51 | 392.67B | ||
| AMGN | AMGEN INC | 14.96 | 176.18B | ||
| GILD | GILEAD SCIENCES INC | 14.84 | 150.84B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.88 | 118.41B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.2 | 81.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.12 | 52.83B | ||
| INSM | INSMED INC | N/A | 37.12B | ||
| NTRA | NATERA INC | N/A | 33.88B | ||
| BIIB | BIOGEN INC | 10.77 | 26.44B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.18 | 21.79B | ||
| INCY | INCYTE CORP | 16.64 | 20.97B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.30B |
Related stock screener links
About CBUS
Company Profile
Cibus, Inc. engages in the research and development of plant traits to seed companies for royalties. The company is headquartered in San Diego, California and currently employs 157 full-time employees. The company went IPO on 2017-07-20. Its business is the development of plant traits for some of the agricultural food crops that help address specific productivity, profitability, sustainability, or yield challenges in farming. Its core technology propriety gene editing platform is called the Rapid Trait Development System (RTDS). The company is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. The company has a pipeline of five productivity traits. The company has developed the productivity trait Pod Shatter Reduction (PSR) in Canola and Winter Oilseed Rape (WOSR) strengthens the sheath around the canola seeds. Its advanced productivity traits, Sclerotinia resistance and HT2 in Canola and WOSR, continue to progress and offer white mold disease resistance and broadleaf weed herbicide tolerance.
Company Info
CIBUS INC
6455 Nancy Ridge Drive
San Diego CALIFORNIA US
Employees: 157
Phone: 18584500008
CIBUS INC / CBUS FAQ
Can you describe the business of CIBUS INC?
Cibus, Inc. engages in the research and development of plant traits to seed companies for royalties. The company is headquartered in San Diego, California and currently employs 157 full-time employees. The company went IPO on 2017-07-20. Its business is the development of plant traits for some of the agricultural food crops that help address specific productivity, profitability, sustainability, or yield challenges in farming. Its core technology propriety gene editing platform is called the Rapid Trait Development System (RTDS). The company is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. The company has a pipeline of five productivity traits. The company has developed the productivity trait Pod Shatter Reduction (PSR) in Canola and Winter Oilseed Rape (WOSR) strengthens the sheath around the canola seeds. Its advanced productivity traits, Sclerotinia resistance and HT2 in Canola and WOSR, continue to progress and offer white mold disease resistance and broadleaf weed herbicide tolerance.
What is the stock price of CIBUS INC today?
The current stock price of CBUS is 2.21 USD. The price increased by 9.41% in the last trading session.
What is the dividend status of CIBUS INC?
CBUS does not pay a dividend.
How is the ChartMill rating for CIBUS INC?
CBUS has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting CBUS stock to perform?
10 analysts have analysed CBUS and the average price target is 14.69 USD. This implies a price increase of 564.62% is expected in the next year compared to the current price of 2.21.
What is the employee count for CBUS stock?
CIBUS INC (CBUS) currently has 157 employees.
CBUS Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to CBUS. When comparing the yearly performance of all stocks, CBUS is one of the better performing stocks in the market, outperforming 73.84% of all stocks.
CBUS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CBUS. CBUS has a bad profitability rating. Also its financial health evaluation is rather negative.
CBUS Financial Highlights
Over the last trailing twelve months CBUS reported a non-GAAP Earnings per Share(EPS) of -2.66. The EPS increased by 82.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.01% | ||
| ROE | -235.91% | ||
| Debt/Equity | 0 |
CBUS Forecast & Estimates
10 analysts have analysed CBUS and the average price target is 14.69 USD. This implies a price increase of 564.62% is expected in the next year compared to the current price of 2.21.
For the next year, analysts expect an EPS growth of 18.82% and a revenue growth 0.81% for CBUS